Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, ...
Pharmaceutical Technology on MSN
Arthrosi gains $153m for development of gout therapy
Arthrosi Therapeutics has completed a series E funding round, amassing $153m, earmarked to advance the clinical development of pozdeutinurad.
Enrollment complete in the replicate REDUCE 1 and REDUCE 2 Phase 3 studies with pivotal data expected in Q2 2026 SAN DIEGO, Oct. 8, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback